Mobile Trading

SUN PHARMACEUTICAL INDUSTRIES LTD.

NSE : SUNPHARMABSE : 524715ISIN CODE : INE044A01036Industry : Pharmaceuticals & DrugsHouse : Sun Pharma
BSE1656.057.15 (+0.43 %)
PREV CLOSE ( ) 1648.90
OPEN PRICE ( ) 1651.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 229233
TODAY'S LOW / HIGH ( )1642.20 1668.40
52 WK LOW / HIGH ( )1555 1960.2
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value ( in Lacs) 3803.77
Dividend Yield(%) 0.97
TTM EPS () 20.00
P/E Ratio 82.81
Book Value () 104.58
Face Value () 1
MCap ( in Mn) 3973418.68
Price/Earning (TTM) 66.60
Price/Sales (TTM) 16.71
Price/Book (MRQ) 15.83
PAT Margin (%) 18.62
ROCE (%) 16.92
Incorporation Year : 01-03 1993
Management Info
Dilip S Shanghvi - Chairman Kirti Ganorkar - Managing Director
Registered Office

Address Sun Pharma Advanced Research Centre (S P A R C),Tandalja, ,
Vadodara,
Gujarat-390012

Phone 0265- 5515500 / 5515600 / 5515700

Email secretarial@sunpharma.com

Website www.sunpharma.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS
10Sep Sun Pharmaceutical’s Halol facility
U.S. Food and Drug Administration (USFDA) has classified Sun Pharmaceuti..
10Sep Sun Pharmaceutical Industries informs
Sun Pharmaceutical Industries has informed that it enclosed Disclosure u..
04Aug Sun Pharmaceutical Industries informs
Sun Pharmaceutical Industries has informed that the exchange has receive..
01Aug Clarification sought from Sun Pharmac
The Exchange has sought clarification from Sun Pharmaceutical Industries..
31Jul Sun Pharmaceutical Industries reports
Sun Pharmaceutical Industries has reported result for first quarter ende..
Financials
in Millions
QTR Jun 25 ANNUAL 25
Net Profit7535.2999999999942826.2
Gross Profit 11848.8 50305.7
Operating Profit 19948.471620.5
Net Sales 56019.6230033.3
ROLLING FORWARD P/E (EOD)
JavaScript chart by amCharts 3.4.219-Sep-2521-Feb-2502-Aug-2408-Jan-2414-Jun-2318-Nov-2226-Apr-2229-Sep-210100200300400500Show all
JavaScript chart by amCharts 3.4.212 Months Rolling Forward P/E (X)
EVENT CALENDAR
peer group
Alivus Life Sciences (BSE)
up  1051.00 (11.01%)
M.Cap ( in Cr)12893.81
Divi's Lab (BSE)
up  6198.65 (1.58%)
M.Cap ( in Cr)164554.68
Ipca Laboratories (BSE)
up  1429.75 (6.86%)
M.Cap ( in Cr)36273.36
Procter&Gamble Healt (BSE)
up  6344.00 (1.21%)
M.Cap ( in Cr)10530.65
Orchid Pharma (BSE)
up  788.55 (9.99%)
M.Cap ( in Cr)3999.46
Shareholding Pattern
NON-INSTITUTION 8.77%
PROMOTERS 54.48%
FI/BANKS/INSURANCE 5.15%
MUTUAL FUNDS/UTI 12.63%
GOVERNMENT 0%
FII 0%

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.